Introduction: Patients with advanced sarcoidosis may develop Pulmonary Hypertension (PH). Sarcoidosis related PH was most frequently seen in patients with fibrotic disease and comes with increased mortality. We describe diagnostic modalities and management strategies used in patients with sarcoidosis associated PH in the United States (US). Methods: We conducted a retrospective study based on a national registry investigating 3,835 respondents to the Foundation for Sarcoidosis Research (FSR-SARC). The registry includes patient surveys completed between June 2014 and August 2019. Summary and univariate analyses were performed. Results: A total of 211 (6%) patients with PH with a mean (±SD) age of 42 (13) years were identified; 139 (66%) were women, 126 (60%) Caucasian and 69 black (33%). Patients with PH were younger (mean age, years +-SD) {42+-13 vs 44+-12; p=0.008}. Patients with PH were more likely to be women (OR: 1.5, 95%CI:1.1-2.0, p=0.006) and less likely to be Caucasian (Caucasian: 5%, Black: 16%, other:15%, p<0.0001).PH therapy: 27 (13%) received phosphodiesterase inhibitors including sildenafil or tadalafil, 12 (6%) received endothelin receptor antagonist including ambrisentan, macitentan or bosentan, 5 (2.4%) received IV therapy including Treprostinil, iloprost or epoprostenol, 3 (1.4%) inhaled treprostinil, 2 (0.9%) received an oral prostacyclin and 2 (0.9%) received riociguat. Sarcoidosis therapy received by patients with PH: 166 (79%) steroids, 96 (46%) cytotoxic medications and/or 40 (19%) TNF inhibitor. Patients with PH were more likely to receive cytotoxic medications (OR: 1.5, 95%CI:1.1-1.9, p=0.008) and TNF inhibitors (OR: 1.7, 95%CI:1.2-2.4, p=0.004). However, there was no significant difference in steroid use between patients with and without PH (OR: 1.2, 95%CI:0.9-1.7, p=0.30). Conclusions: Non-Caucasian, younger females with sarcoidosis were more at risk for PH. Phosphodiesterase inhibitors are the most commonly used class in this population. Patients with PH were more likely to receive more aggressive sarcoidosis therapy with cytotoxic meds +/-TNF inhibitors.